AzurRx BioPharma Stock Quote AZRX - Stock Price, News, Charts, Message Board, Trades

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

3.45

Bid

3.41

Ask

3.51

Volume

0.00 Day's Range 0.00

0.00 52 Week Range 0.00

Market Cap

46.575M

Previous Close

3.45

Open

Last Trade

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

Shares Outstanding

13,500,000

Dividend Yield

PE Ratio

-2.48

Earnings Per Share (EPS)

-1.19

Revenue

Net Profit

-16.1M

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.enterothera.com

Headquarters

Dover, Delaware, USA

Founded

AzurRx BioPharma to Change Corporate Name to First Wave BioPharma Today

BOCA RATON, Fla., Sept. 21, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX) (“First Wave” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...

AzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Acquisition of First Wave Bio and Creation of First Wave BioPharma

BOCA RATON, Fla., Sept. 14, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...

AzurRx BioPharma Announces Acquisition of First Wave Bio and its Proprietary Niclosamide Formulations Targeting Multi-Billion Dollar Inflammatory Bowel Disease Indications

AzurRx BioPharma to be renamed “First Wave BioPharma” and trade under new NASDAQ ticker symbol, “FWBI” Three IBD clinical indications, including ulcerative colitis and Crohn’s disease, added to...

AzurRx BioPharma Announces Reverse Stock Split

BOCA RATON, Fla., Sept. 10, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the...

AzurRx BioPharma Activates New Clinical Trial Sites in India for Phase 2 RESERVOIR Trial Evaluating Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

BOCA RATON, Fla., Sept. 10, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic...

AzurRx BioPharma Announces Positive Results from Independent Data Monitoring Committee Review of Safety Data from Part 1 of RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

Review of Interim Safety Data Concluded with Favorable Recommendation to Continue RESERVOIR Trial as Planned Part 2 of RESERVOIR Trial to Enroll Up to 150 Patients to Evaluate Efficacy of FW-1022...

AzurRx BioPharma to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference

BOCA RATON, Fla., Sept. 07, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted...

AzurRx BioPharma Announces Positive Topline Data For Phase 2 MS1819 Combination Therapy Trial in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency (EPI)

MS1819 and PERT combination therapy achieves primary and secondary outcome measure endpointsStudy data indicates clinically meaningful improvement in coefficient of fat absorption (CFA) primary...

AzurRx BioPharma Announces WHO Publication of “Adrulipase Alfa” as International Nonproprietary Name for MS1819

BOCA RATON, Fla., Aug. 17, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted...

AzurRx BioPharma Announces Appointment of Terry Coelho to its Board of Directors

BOCA RATON, Fla., Aug. 16, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

AZRX - Frequently Asked Questions (FAQ)

What is the current AzurRx BioPharma share price?

The current share price of AzurRx BioPharma is $ 3.45

How many AzurRx BioPharma shares are in issue?

AzurRx BioPharma has 13,500,000 shares in issue

What is the market cap of AzurRx BioPharma?

The market capitalisation of AzurRx BioPharma is USD 46.58M

What is the 1 year trading range for AzurRx BioPharma share price?

AzurRx BioPharma has traded in the range of $ 0.00 to $ 0.00 during the past year

What is the PE ratio of AzurRx BioPharma?

The price to earnings ratio of AzurRx BioPharma is -2.48

What is the reporting currency for AzurRx BioPharma?

AzurRx BioPharma reports financial results in USD

What is the latest annual profit for AzurRx BioPharma?

The latest annual profit of AzurRx BioPharma is USD -16.1M

What is the registered address of AzurRx BioPharma?

The registered address for AzurRx BioPharma is 850 NEW BURTON ROAD, SUITE 201, KENT, DOVER, DELAWARE, 19904

What is the AzurRx BioPharma website address?

The website address for AzurRx BioPharma is www.enterothera.com

Which industry sector does AzurRx BioPharma operate in?

AzurRx BioPharma operates in the PHARMACEUTICAL PREPARATIONS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
ONCBeiGene Ltd	183.00 (726.19%)	67.84k
RAINRain Enhancement Technologies Holdco Inc	5.38 (344.63%)	139.97k
NITON2OFF Inc	$ 1.0899 (339.48%)	568.71M
CTCXCarmell Corporation	$ 0.715001 (156.18%)	298.46M
AEIAlset Inc	$ 2.0354 (99.55%)	40.69M
NMRANeumora Therapeutics Inc	$ 1.935 (-81.75%)	36.89M
THCHTH International Limited	$ 0.714296 (-79.88%)	39.94k
SISIShineco Inc	$ 2.04 (-54.97%)	1.54M
SIDUSidus Space Inc	$ 2.9699 (-39.39%)	11.31M
BDMDBaird Medical Investment Holdings Ltd	$ 4.9594 (-34.74%)	3.54M
NITON2OFF Inc	$ 1.085 (337.50%)	568.77M
CTCXCarmell Corporation	$ 0.7249 (159.73%)	298.46M
MBIOMustang Bio Inc	$ 0.2381 (34.52%)	278.04M
CGBSCrown LNG Holdings Ltd	$ 0.6248 (56.16%)	271.19M
BGLCBioNexus Gene Lab Corporation	$ 0.5144 (83.91%)	185.38M